• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Is J&J in the hunt for Boston Scientific? | Acquisitions Roundup

Is J&J in the hunt for Boston Scientific? | Acquisitions Roundup

September 15, 2011 By MassDevice staff

Johnson & Johnson
Boston Scientific

Could the amicable deal between bitter rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) over Michael Mahoney leaving J&J to helm BSX signal an upcoming acquisition?

Opinions are divided on Wall Street, with at least one analyst wondering if a deal could be in the works and others casting doubt on the speculation.

In a late-breaking announcement Sept. 13, Boston Scientific said Mahoney will become president effective Oct. 17 and take the corner office in November 2012. The unusual transition period allows Mahoney to learn the business and also helps side-step any anti-competition covenants in his contract with J&J. The news came as a surprise given the duo’s long-standing battles over the drug-eluting coronary stent market, which Johnson & Johnson pioneered – only to see BSX emerge with the leading market share.

Sign up to get our free newsletters delivered right to your inbox

The amity might indicate that J&J is ultimately interested in buying its smaller peer, according to Wells Fargo analyst Larry Biegelsen. The "friendly agreement" that’s sending Mahoney to BSX’s Natick, Mass. HQ could "fuel additional speculation" that a merger is afoot, Biegelsen wrote in a note to investors yesterday.

Other analysts on The Street were not so sure.

"An interesting theory but sounds like pure speculation," Sanford Bernstein analyst Derrick Sung told the Wall Street Journal, adding that Mahoney got the job for his willingness to continue the turnaround plan put in place by the man he’s succeeding, Ray Elliott.

“The last thing you want is a new CEO coming in who says, ‘I’m the new CEO, I’m going to blow up this plan,'” Elliott told analysts yesterday at the Morgan Stanley Global Health Conference in New York. "Mike was essentially, from very early in the game, almost a perfect match – and that’s culturally, too."

Another un-named analyst told the Journal that J&J isn’t interested in acquiring Boston Scientific and that Mahoney is leaving Johnson & Johnson on less-than-friendly terms.

But if J&J isn’t interested in Boston Scientific, it is interested in broadening its portfolio of cardiac devices to include heart pumps and heart valves, according to CFO Dominic Caruso.

“Both [technologies] are interesting. We are interested in looking at them,” Caruso said at the conference Sept. 13. “Unfortunately they are overvalued today.”

That could make targets of heart pump makers Abiomed Inc. (NSDQ:ABMD), HeartWare International (NSDQ:HTWR), Thoratec Corp. (NSDQ:THOR) and World Heart Corp. (NSDQ:WHRT) on the cardiac assist device side. Here’s a look at how each company shapes up in terms of price/earnings ratio:


Company Price EPS P/E
Abiomed $11.23 -$0.28 -40
HeartWare $55.73 -$2.48 -22
Thoratec $31.40 $1.07 29
World Heart $0.43 -$0.32 -1.34

By this measure, J&J would have to put some of its slaes muscle behind Abiomed, Thoratec is an expensive purchase for J&J (by way of comparison, the Dow Jones medical device index has a P/E ratio of 3.2), which is making price one of its top considerations, according to finance chief Caruso. But with their earnings under water, J&J would have to spend on R&D and put its sales and marketing muscle behind the heart pumps made by the other three firms.

And J&J’s penchant for low pricing could make a deal for Edwards Lifesciences (NSDQ:EW) less palatable too, even though the heart valve pioneer is leading the race to bring the first catheter-delivered replacement aortic valve to the U.S. market. Here’s a look at the P/E ratios of Edwards and other heart valve makers:


Company Price EPS P/E
Abbott $51.05 $3.28 16
Edwards $76.25 $1.96 39
Medtronic $34.20 $2.87 12
St. Jude Medical $43.43 $2.68 16

Another name to put into the heart valve mix is privately owned On-X Life Technologies, which won 510(k) clearance in January for a version of its ascending aortic prosthesis valve.

Here’s a roundup of other merger & acquisition news

Mergers and Acquisitions
  • Integra to pay $65 million for Ascension Orthopedics
    Integra LifeSciences Holdings Corp. (NSDQ:IART) agreed to pony up about $65 million in cash for Ascension Orthopedics Inc. and its foot, hand and shoulder devices. Read more
  • Solta Medical buys LipoSonix from Medicis for $15 million
    Solta Medical Inc. (NSDQ:SLTM) agreed to pay $15 million in up-front cash and another $5 million in milestone payments for Medicis Pharmaceutical Corp.’s (NYSE:MRX) Medicis Technologies Corp., formerly LipoSonix. Read more
  • Vasomedical buys Chinese suppliers
    Vasomedical Inc. (PINK:VASO) paid $1 million in cash and 7.4 million shares of stock to acquire the holding company that owns two of its suppliers in China. Read more
  • Hill-Rom pays $20 million for French, Swiss distributors
    Hill-Rom Holdings Inc. (NYSE:HRC) paid about $20 million to acquire Liko France SAS, Item SA and Liko Care AG, which distribute its Liko patient mobility products in France and Switzerland.  Read more
  • Bruker to buy CETR
    Bruker Corp. (NSDQ:BRKR) inked a deal to buy materials research firm Center for Tribology Inc. for an undisclosed amount. Read more
  • Elekta closes Nucletron deal
    Elekta AB (STO:EKTAB) closed its buyout of brachytherapy planner Nucletron for about $525.5 million (€365 million) in cash. Read more
  • DGT Holdings deals Italian subsidiary to VIV for $22.5 million
    DGT Holdings Corp. (OTC:DGTC) sold its Italian subsidiary Villa Sistemi Medicali spa to VIV srl for about $22.5 million. Read more

Filed Under: Mergers & Acquisitions, News Well Tagged With: Ascension Orthopedics, Boston Scientific, Bruker Corp., Center for Tribology Inc., DGT Holdings, Integra LifeSciences, Johnson and Johnson, Medicis Aesthetics, Nucletron, Solta Medical Inc., Vasomedical Inc.

In case you missed it

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance

RSS From Medical Design & Outsourcing

  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy